Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTIS2023-508230-33-00
CTIS2023-508230-33-00Active, not recruitingPhase 1

TETRALITE-Ib

iteVax B.V.0 sites70 target enrollmentStarted: October 12, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
70
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 65+ (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
iteVax B.V.

Similar Trials

Active, not recruiting
Phase 1
Treatment of diabetic neuropathy with liraglutide
EUCTR2013-004375-12-DKCenter of Mech-Sense
Active, not recruiting
Phase 1
A study of oral EMA401 in the treatment of pain following shingles to see if EMA401 can reduce the level of pain.
EUCTR2011-000977-29-BGSpinifex Pharmaceuticals Pty Ltd172
Completed
Phase 1
A double-blind, placebo-controlled, randomised trial to determine the ocular pharmacokinetics and safety of oral FT011 in patients with glaucoma.
ACTRN12618000033246Occurx Pty Ltd8
Active, not recruiting
Not Applicable
A study of oral EMA401 in the treatment of pain following shingles to see if EMA401 can reduce the level of pain.postherpetic neuralgiaMedDRA version: 14.0Level: PTClassification code 10036376Term: Post herpetic neuralgiaSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2011-000977-29-CZSpinifex Pharmaceuticals Pty Ltd172
Active, not recruiting
Not Applicable
A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.
EUCTR2006-004736-79-CZAntisense Therapeutics Ltd.80